Dr Andrew Brockway is the Chief Executive Officer for Doherty Clinical Trials Ltd. Andrew has more than 20 years research and industry experience and has held local and global roles in research and development roles in large pharmaceutical companies, early phase research institutions, and successfully lead business development activities for a global contract research organisation (CRO). He has expertise in the development and operational delivery of global clinical activities across Asia Pacific, Europe, Africa and North America. He is passionate about the development of new medicines for diseases of unmet medical needs, and spent several years working on clinical trials for malaria and tuberculosis vaccines. He is a Non-Executive Director on the board of a not for profit organisation that supports research into treatments and a cure for a rare neurological disease.